High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab

The humanized non-depleting anti-CD4 monoclonal antibody Tregalizumab (BT-061) is able to selectively activate the suppressive function of regulatory T cells and has been investigated up to phase IIb in clinical trials in patients suffering from rheumatoid arthritis (RA). A pharmacokinetic–pharmacod...

Descripción completa

Detalles Bibliográficos
Autores principales: Heim, Katharina, Dälken, Benjamin, Faust, Stefanie, Rharbaoui, Faiza, Engling, Andre, Wallmeier, Holger, Dingermann, Theodor, Radeke, Heinfried H, Schüttrumpf, Jörg, Gutscher, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192061/
https://www.ncbi.nlm.nih.gov/pubmed/28090323
http://dx.doi.org/10.1038/cti.2016.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192061/
https://www.ncbi.nlm.nih.gov/pubmed/28090323
http://dx.doi.org/10.1038/cti.2016.69

Ejemplares similares